A randomised comparison of safety and efficacy of triple therapy for 12 weeks, followed by 12 or 36 additional weeks of peginterferon alfa 2b and ribavirin in HCV patients
Latest Information Update: 28 Dec 2013
At a glance
- Drugs Peginterferon alfa-2b/ribavirin (Primary) ; Telaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 24 Dec 2013 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan record.
- 29 Dec 2011 New trial record